Michael W. Dunne - Net Worth and Insider Trading

Michael W. Dunne Net Worth

The estimated net worth of Michael W. Dunne is at least $176,319 dollars as of 2024-05-04. Michael W. Dunne is the Director of Iterum Therapeutics PLC and owns about 113,754 shares of Iterum Therapeutics PLC (ITRM) stock worth over $176,319. Details can be seen in Michael W. Dunne's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Michael W. Dunne has not made any transactions after 2023-12-22 and currently still holds the listed stock(s).

Transaction Summary of Michael W. Dunne

To

Michael W. Dunne Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael W. Dunne owns 2 companies in total, including Iterum Therapeutics PLC (ITRM) , and Vaxart Inc (VXRT) .

Click here to see the complete history of Michael W. Dunne’s form 4 insider trades.

Insider Ownership Summary of Michael W. Dunne

Ticker Comapny Transaction Date Type of Owner
ITRM Iterum Therapeutics PLC 2023-12-22 Chief Scientific Officer
VXRT Vaxart Inc 2015-09-21 director

Michael W. Dunne Latest Holdings Summary

Michael W. Dunne currently owns a total of 1 stock. Michael W. Dunne owns 113,754 shares of Iterum Therapeutics PLC (ITRM) as of December 22, 2023, with a value of $176,319.

Latest Holdings of Michael W. Dunne

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ITRM Iterum Therapeutics PLC 2023-12-22 113,754 1.55 176,319

Holding Weightings of Michael W. Dunne


Michael W. Dunne Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael W. Dunne has made a total of 5 transactions in Iterum Therapeutics PLC (ITRM) over the past 5 years, including 4 buys and 1 sells. The most-recent trade in Iterum Therapeutics PLC is the acquisition of 25,000 shares on December 22, 2023, which cost Michael W. Dunne around $35,000.

Insider Trading History of Michael W. Dunne

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael W. Dunne Trading Performance

GuruFocus tracks the stock performance after each of Michael W. Dunne's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael W. Dunne is -21.25%. GuruFocus also compares Michael W. Dunne's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael W. Dunne within 3 months outperforms 1 times out of 7 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Michael W. Dunne's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Michael W. Dunne

Average Return

Average return per transaction

Outperforming Transactions

0 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -11.92
Relative Return to S&P 500(%) -11.81

Michael W. Dunne Ownership Network

Ownership Network List of Michael W. Dunne

No Data

Ownership Network Relation of Michael W. Dunne


Michael W. Dunne Owned Company Details

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Michael W. Dunne is the Chief Scientific Officer of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include director & President & CEO Fishman Corey N. , Chief Medical Officer Sailaja Puttagunta , and Chief Financial Officer Judith M. Matthews .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Michael W. Dunne made 3 insider transaction in Iterum Therapeutics PLC (ITRM) with a net purchase of 55,000. Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 10,000 shares made by Fishman Corey N. , a net sale of 3,365 shares made by Sailaja Puttagunta ,

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,365 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 61,635 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Iterum Therapeutics PLC Insider Transactions

No Available Data

Michael W. Dunne Mailing Address

Above is the net worth, insider trading, and ownership report for Michael W. Dunne. You might contact Michael W. Dunne via mailing address: Durata Therapeutics, Inc., 89 Headquarters Plaza North, 14th Floor, Morristown Nj 07960.

Discussions on Michael W. Dunne

No discussions yet.